Overview of Zanamivir

Property	Description
Active ingredient	Zanamivir (INN)
Form	Inhalation powder, Dry Powder Inhaler (DPI)
Pharmacological class	Antiviral Agent (Neuraminidase Inhibitor)
General purpose	Limiting viral spread to reduce illness duration
Origin	Synthetic compound (Sialic acid analogue)

What Type of Medicine is Zanamivir?

Zanamivir is a synthetic compound that is classified as a prescription-only antiviral agent intended to counteract specific viral infections. The drug belongs to the specific pharmacological class known as neuraminidase inhibitors. This places it among medications that selectively target a crucial enzyme necessary for viral propagation. Zanamivir was notably the first neuraminidase inhibitor to be developed commercially, giving it a distinctive role in the history of this type of antiviral treatment.

Composition, Physical Form, and Delivery

The core component is the active ingredient, Zanamivir (INN), a fine, micronized powder. This product is manufactured as a single-active ingredient product and is supplied as an inhalation powder delivered via a dry powder inhaler (DPI) device. This unique inhaled delivery route directly targets the respiratory tract, a key differentiating feature from other oral antivirals in the same class. The composition includes the Zanamivir compound combined with lactose monohydrate, which acts as a carrier powder to ensure the proper dispersion of the drug during inhalation.

General Purpose: Blocking Viral Spread

The general purpose of Zanamivir is to contain the infection, thereby helping to limit the duration and severity of the associated illness. Zanamivir achieves this by acting as a selective inhibitor of neuraminidase, an enzyme that the virus requires to detach from an infected cell and travel to new, healthy cells. This inhibition mechanism effectively interrupts the viral replication process, thereby impeding the cell-to-cell spread of the infection within the respiratory system.

What side effects are possible with Zanamivir?

Possible Side Effects and Safety Information

Zanamivir’s safety profile is documented by regulatory authorities, encompassing adverse reactions reported in clinical trials and those identified during post-marketing surveillance. This information is classified by frequency and the body system affected, providing a non-advisory description of possible effects.

Documented Adverse Reactions

Side effects observed in clinical trials, reported at an incidence greater than placebo, include sinusitis and dizziness in treatment studies, and fever/chills, arthralgia (joint pain), and articular rheumatism in prophylaxis studies. These are considered among the most common documented reactions.

Post-marketing reports document serious adverse reactions where the frequency cannot be reliably estimated. These events involve several system organ classes, including bronchospasm and dyspnea (respiratory system), and neuropsychiatric events such as seizures, delirium, and abnormal behavior (nervous system). Serious allergic reactions, including anaphylaxis and severe cutaneous reactions like Stevens-Johnson syndrome, have also been reported.

Official Safety Constraints

The regulatory label includes specific limitations on use. Zanamivir is not recommended for individuals with underlying airways disease (e.g., asthma or COPD) due to the risk of serious, sometimes fatal, bronchospasm. A formal contraindication exists for individuals with a history of allergic reaction to any ingredient, which includes milk proteins found in the lactose excipient. The label also notes that neuropsychiatric events may occur early in the influenza illness, particularly in pediatric patients.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented presentations of inhaled Zanamivir overdose are stated as being similar to the symptoms reported with therapeutic doses or those manifestations associated with the underlying influenza illness. However, regulators emphasize that severe and life-threatening events have been reported in association with Zanamivir use.

Overdose Outcome	Severity and Required Action (as labeled)
Respiratory Decline	Serious, sometimes fatal, cases of acute bronchospasm and decline in respiratory function have been reported. Immediate medical evaluation must be sought if these symptoms develop, and the drug should be discontinued.
Neuropsychiatric Events	Symptoms such as convulsions, delirium, hallucinations, and abnormal behavior have been reported. Patients, particularly children and adolescents, must be monitored closely for behavioral changes, as these events may occur in the setting of overdose.

If any hypersensitivity reaction is suspected, such as oropharyngeal edema or serious skin rashes, the medicine must be discontinued immediately. The management of overdose is supportive and should be guided by a poisons center. There is no specific antidote known for Zanamivir, but official data notes that the compound is expected to be removable by haemodialysis due to its physiochemical properties.

The regulatory profile defines when urgent medical attention is needed by specifically pointing to potentially life-threatening respiratory distress, mandating immediate drug cessation and medical evaluation under these conditions.

Therapeutic Uses of Zanamivir

Main Uses and Benefits of Zanamivir

Zanamivir is an antiviral medication specifically designed to target the influenza virus. It belongs to a class of drugs known as neuraminidase inhibitors. By blocking the neuraminidase enzyme, the medication prevents the virus from escaping infected cells and spreading to healthy cells throughout the respiratory tract.

Treatment of Acute Influenza

Zanamivir is primarily used for the treatment of acute, uncomplicated illness caused by influenza A and B viruses. It is intended for individuals who have been symptomatic for no more than two days. When administered early in the course of the infection, the medication can help reduce the duration of flu symptoms, such as fever, cough, sore throat, and muscle aches.

Prevention of Influenza

In addition to treating active infections, Zanamivir is used as a preventive measure (prophylaxis) against influenza. This application is typically relevant in the following scenarios:

Household Exposure: Reducing the risk of infection in individuals who have been in close contact with someone diagnosed with the flu.
Community Outbreaks: Providing protection during seasonal outbreaks, particularly for those who may be at a higher risk of infection.

Key Benefits

The primary benefit of Zanamivir is its ability to interfere with the viral replication process. By limiting the spread of the virus within the body, the medication can:

Shorten Recovery Time: Decrease the total number of days a patient feels ill.
Symptom Mitigation: Reduce the overall severity of the respiratory and systemic symptoms associated with the flu.
Viral Specificity: Act directly on the influenza virus without affecting the body's natural immune response to other types of infections.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory criteria for Zanamivir (inhalation powder) define specific populations who are eligible for treatment or prophylaxis and those who must not use the medicine.

Contraindications and Restrictions

Category	Official Regulatory Status
Absolute Contraindication	Patients with known severe hypersensitivity or allergy to Zanamivir or to any component of the product, including lactose or milk proteins
Use Not Recommended	Individuals with underlying airways disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), due to the documented risk of serious bronchospasm
Conditional Use	If used in patients with airways disease, it requires careful respiratory monitoring and the immediate availability of a fast-acting bronchodilator

Age-Related Eligibility

Purpose	Minimum Age for Use (Established Safety/Efficacy)
Treatment	7 years of age and older
Prophylaxis	5 years of age and older

Safety and effectiveness for both indications are not established in patients below these respective age thresholds. For older adults, no specific dosage adjustment is required, but increased sensitivity to medication effects may warrant caution. The regulatory status for pregnancy and lactation is generally defined by balancing the drug's potential benefit against the potential risk.

What should I know about interactions with other medicines?

Zanamivir has a low potential for clinically significant pharmacokinetic drug interactions. This is primarily due to the drug’s metabolic profile: it is not metabolized by the liver, and it is eliminated predominantly unchanged by the kidneys. Furthermore, in vitro studies show that Zanamivir does not act as a substrate, inhibitor, or inducer of the major Cytochrome P450 (CYP) isoenzymes (including CYP1A1/2, 2C9, 2D6, and 3A4) or key renal and hepatic transporters. Therefore, Zanamivir is not expected to affect the concentration of other medicines that are metabolized by these pathways, and similarly, other medicines are not expected to significantly alter Zanamivir's concentration in the blood.

Interactions with Vaccines

Live Attenuated Influenza Vaccine (LAIV): An interaction is possible because Zanamivir is an antiviral that inhibits viral replication. The live vaccine should not be administered until at least 48 hours following cessation of Zanamivir therapy. Conversely, Zanamivir should not be started until two weeks after administration of the live attenuated influenza vaccine, unless there is a clear medical indication to start Zanamivir immediately.

Inactivated Trivalent Influenza Vaccine: Clinical studies have shown no evidence of reduced serological response or interference when Zanamivir is administered with the inactivated (injectable) influenza vaccine. The inactivated vaccine can be used during Zanamivir therapy.

Mechanism of Action

How Zanamivir Works: Core Mechanisms

Zanamivir functions as a sialic acid analog, structurally mimicking the natural substrate of the neuraminidase (NA) enzyme found on the surface of influenza A and influenza B viruses. The drug acts as a specific competitive inhibitor of the viral NA enzyme. By binding directly to the enzyme's active site, zanamivir blocks the catalytic function of neuraminidase, preventing it from cleaving the sialic acid receptors.

This inhibition of the NA enzyme stops the required bond breakage that allows newly formed viral particles to detach from the surface of the infected host cell. The immediate mechanistic consequence is the aggregation and immobilization of the new virions on the cell membrane. This results in the localized containment of the viral particles, physically restricting their ability to progress to an uninfected cell and initiating a new cycle of infection.

Dosage and Administration Information

How Zanamivir is Used

Zanamivir is primarily administered as an inhalation powder through a specialized Diskhaler® device, which directs the medication to the respiratory tract. This oral inhalation route is the officially approved method for the commercial product. An intravenous (IV) formulation has been used in specific clinical settings, typically under emergency or compassionate use protocols for severe cases where inhaled administration is not possible.

Standard Administration Patterns

The standard dose for both treatment and prophylaxis is 10 mg, delivered as two separate inhalations of 5 mg each. Use must adhere to strict timeframes relative to the influenza infection:

Treatment Initiation: Must begin within 48 hours of the onset of symptoms.
Duration: The established course for treatment is 5 days.

Usage Context	Standard Dose	Frequency	Duration Pattern
Treatment	10 mg	Twice daily (12 -hour intervals)	5 days course
Prophylaxis (Prevention)	10 mg	Once daily	10 to 28 days (context dependent)

Procedural and Population Requirements

Zanamivir must only be inhaled using the designated Diskhaler® device and is not suitable for administration via standard nebulizers or ventilators. Doses should be taken at approximately the same time each day. For pediatric use, the drug is approved for treatment in patients aged 7 years and older, and for prophylaxis in those aged 5 years and older. Due to minimal systemic absorption, the dose of the inhaled product does not typically require adjustment in the presence of hepatic or renal impairment.

Recent Clinical Evidence

Zanamivir: Recent Clinical Evidence

Research Evidence for Treatment of Uncomplicated Influenza

The primary evidence is based on short-term, randomized, controlled clinical trials (RCTs) that was studied for the use of Zanamivir initiated after symptom onset in otherwise healthy adults and children. These trials research examined patient-reported outcomes, specifically measuring the Time to Alleviation of Symptoms (TTAS). Some trials reported patterns where the time required for symptom resolution was measured to be less in the groups studied, though this finding was not consistent across all research. The evidence provides insight into acute symptom patterns, but research is limited in characterizing more serious endpoints, such as preventing the need for hospital admission or pneumonia.

Research Evidence for Influenza Prevention (Prophylaxis)

Studies were conducted to examine whether the intervention was evaluated for its association with a lower occurrence of symptomatic, laboratory-confirmed influenza in individuals following exposure. Studies reported patterns where the rate of symptomatic, laboratory-confirmed influenza was measured to be lower in the group studied compared to the control group. Research also explored short-term symptom changes during periods of potential exposure. However, the existing evidence is limited in characterizing the effect of the medicine on preventing asymptomatic influenza infection.

Evidence in Special Populations and Areas of Uncertainty

Research was studied for specific patient groups, including older adults and individuals with underlying chronic medical conditions. This data often relies on pooled analyses of multiple trials. The research explored patterns suggesting that the differences in measured outcomes for these high-risk subgroups may differ from those observed in the general population. However, some findings in older adults (aged 65 and over) regarding symptomatic outcomes were reported as being similar to those observed in the control groups. Definitive conclusions regarding outcomes like hospitalization or mortality remain uncertain due to limited specific studies. The follow-up durations were limited in many key trials, meaning long-term effects are not fully established.

Key Studies & References

Zanamivir Inhalation Powder Drug Information - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Zanamivir (FAQ)

Q: Is Zanamivir safe to use during pregnancy?

A: Regulatory information indicates it is not fully known whether Zanamivir may cause harm to an unborn baby. The decision to use this medicine during pregnancy is determined by a healthcare provider, balancing the potential benefit against the potential risk. Animal studies found no evidence of toxicity, and post-marketing data for this drug class generally have not indicated an increased risk of major birth defects.

Q: Do you need a prescription for Zanamivir?

A: Yes, Zanamivir is classified as a prescription-only medicine. Authorization from a licensed healthcare provider is required to obtain and use it.

Q: Does taking Zanamivir affect the effectiveness of the flu shot?

A: The official instructions for use differ based on the type of influenza vaccine. The inactivated (injected) flu vaccine can be given at any time, even during Zanamivir treatment. However, the regulatory label specifies that the live attenuated (nasal spray) flu vaccine should not be administered until at least 48 hours following the cessation of Zanamivir therapy.

Q: Does Zanamivir cause drowsiness or affect my ability to drive?

A: Official information lists dizziness as one of the documented side effects. Official safety constraints caution against driving, operating machinery, or engaging in activities requiring alertness if dizziness or other central nervous system effects are experienced.

Q: Can Zanamivir be used to treat other viral infections besides influenza?

A: Regulatory documents specify that Zanamivir is only indicated and approved for use in illnesses caused by Influenza Virus A and B. Its efficacy against other viral infections has not been established.

Q: What should I do if I miss a dose of Zanamivir?

A: Instructions for a missed dose are provided in the official patient information. Generally, if a dose is missed, regulatory guidance advises taking it as soon as possible. If it is less than 2 hours before the next scheduled dose, skipping the missed dose and resuming the regular schedule is advised. It is specified that a double dose should not be taken to make up for a missed dose.

Q: Are the side effects of Zanamivir generally mild or severe?

A: Zanamivir has common documented side effects such as sinusitis and dizziness, and also reports of rare but serious adverse events from post-marketing surveillance. These serious events include severe breathing difficulties (bronchospasm), severe allergic reactions, and neuropsychiatric events.

Q: What should I do if I have a severe allergic reaction to Zanamivir?

A: Official safety constraints state that if an allergic reaction is suspected—including symptoms like trouble breathing, hives, or swelling of the face/throat—use of the medication should be discontinued and emergency care should be sought immediately.

Q: Is it possible for the flu virus to become resistant to Zanamivir?

A: Yes. Regulatory documents acknowledge that influenza viruses change over time. The emergence of resistance mutations in the virus is possible and could potentially decrease the effectiveness of the drug over time.

Q: Can I use my regular asthma inhaler right before or after using Zanamivir?

A: Official safety constraints specify that if an inhaled bronchodilator (such as an asthma rescue inhaler) is regularly used, it should be administered before Zanamivir. This sequencing is intended to help minimize the risk of serious breathing problems.

Q: Why is Zanamivir sometimes given for a longer time to people who are immunocompromised?

A: The regulatory label indicates that Zanamivir is approved for prophylaxis (prevention) for a duration of up to 28 days, particularly during community outbreaks. The label itself does not tie this extended duration specifically to the treatment of immunocompromised patients.

Q: Has Zanamivir been studied in very young infants?

A: According to regulatory evidence, the safety and effectiveness of Zanamivir have not been established for treatment in pediatric patients under 7 years old, or for prophylaxis (prevention) in those under 5 years old.

Q: Does Zanamivir have any known interaction with oral contraceptives?

A: Regulatory studies suggest Zanamivir has a low potential for drug interactions. This is because it is not significantly metabolized by the major liver enzymes (CYP enzymes) that break down most medicines, including hormonal contraceptives.

Q: Is Zanamivir available in a pill form in any country?

A: The commercially approved and available product is an inhalation powder for oral inhalation only. Although an intravenous (IV) formulation has been used in specific clinical settings, it is not the standard, approved drug for the general public.

Q: Do you still need to get a flu shot even if you've taken Zanamivir previously?

A: Yes. Official limitations state that Zanamivir is not a substitute for getting a yearly flu shot. Health authorities still recommend annual vaccination as the primary method for preventing influenza.

Q: Does Zanamivir interact with common heart medications?

A: Official information indicates that Zanamivir has a low potential for clinically significant drug interactions. This is because the drug is eliminated mostly unchanged by the kidneys and does not rely on the major liver enzymes (CYP enzymes) that metabolize most cardiac medications.

Q: Is it safe to breastfeed while using Zanamivir?

A: No human data is currently available to definitively assess the presence of Zanamivir in human milk or its effects on the breastfed infant. However, the regulatory risk summary suggests the risk to the infant may be low due to the drug’s poor absorption when taken orally.

Q: Can Zanamivir be used for flu symptoms that are already severe?

A: Zanamivir is indicated for the treatment of uncomplicated acute illness due to the flu virus. Regulatory documents note that the use of the standard inhaled product for treating severe symptoms or complications has not been established.

Q: Are there any long-term effects from using Zanamivir?

A: The key clinical trials that led to the drug's approval had limited follow-up periods. Therefore, according to the official product information, the long-term effects of the medicine are not fully established by the existing regulatory evidence.

How should Zanamivir be stored and disposed of?

How to Store and Dispose of Zanamivir

Zanamivir inhalation powder (Relenza) must be stored under specific conditions to maintain stability and effectiveness.

Storage Requirements

Storage Temperature: Store the medicine at room temperature, specifically not above 30°C (86°F). Avoid storing the product in environments where it may be exposed to extreme heat.

Packaging and Protection: Keep the powder in its original packaging, which includes the blister pack and the DISKHALER device. The powder-containing blisters must not be punctured until immediately before a dose is taken. Do not use the medicine after the labeled expiration date.

Child Safety: It is mandatory to keep Zanamivir out of the sight and reach of children.

Disposal Instructions

Unused or expired Zanamivir must be disposed of according to local requirements. Do not dispose of the medicine via wastewater (toilet or sink) or household trash. Consult a pharmacist for guidance on approved drug take-back or collection programs.

Zanamivir